Condensed Consolidated Balance Sheet - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 1,008	$ 12
Accounts receivable (net of allowance for doubtful accounts of $8 in 2021 and $18 in 2020)	1,498	1,038
Inventories (excludes inventories of $60 in 2021 and $127 in 2020 classified in Other Assets)	918	913
Other current assets	905	930
Current assets of discontinued operations	0	674
Total current assets	4,329	3,567
Property, plant and equipment, net	967	984
Goodwill	4,603	4,603
Other intangibles, net	683	503
Other assets	753	361
Noncurrent assets of discontinued operations	0	91
Assets	11,335	10,109
Current Liabilities
Current portion of long-term debt	39	0
Trade accounts payable	1,673	259
Accrued and other current liabilities	1,082	659
Due to related party	0	1,339
Income taxes payable	335	288
Current liabilities of discontinued operations	0	128
Total current liabilities	3,129	2,673
Long-term debt	9,259	0
Deferred income taxes	59	128
Other noncurrent liabilities	506	1,739
Noncurrent liabilities of discontinued operations	0	83
Commitments and Contingencies
Organon & Co. Equity
Common stock, $0.01 par value Authorized - 500,000,000 Issued and outstanding - 253,545,051	3	0
Additional paid-in capital	0	0
Accumulated deficit	(1,128)	0
Net investment from Merck & Co., Inc.	0	6,108
Accumulated other comprehensive loss	(493)	(622)
Total Equity	(1,618)	5,486
Liabilities and Equity	$ 11,335	$ 10,109